Use of risk scores to identify lower and higher risk subsets among COMPASS‐eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry

BACKGROUND: The COMPASS trial showed a reduction of ischemic events with low‐dose rivaroxaban and aspirin in chronic coronary syndromes (CCS) compared with aspirin alone, at the expense of increased bleeding. HYPOTHESIS: The CHA(2)DS(2)VaSc Score, REACH Recurrent Ischemic (RIS), and REACH Bleeding R...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cardiol
Autores principales: Darmon, Arthur, Ducrocq, Gregory, Jasilek, Adam, Feldman, Laurent, Sorbets, Emmanuel, Ferrari, Roberto, Ford, Ian, Tardif, Jean‐Claude, Tendera, Michal, Fox, Kim M., Steg, Philippe Gabriel
Formato: Artigo
Lenguaje:Inglês
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Clinical Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7803362/
https://ncbi.nlm.nih.gov/pubmed/33274779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23505
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares